UNH
UnitedHealth Group Incorporated
UNH has the edge over XTNT overall, supported by stronger fundamentals and lower modeled downside.
XTNT
Xtant Medical Holdings, Inc.
XTNT's outlook is improving, though it still trails on the overall score.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
XTNT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
XTNT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
XTNT PE Valuation
XTNT has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
XTNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
XTNT has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over XTNT on earnings quality, reporting a profit while its opponent remains loss making.
XTNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.08 | -$0.04 |
| Q1 2026 | $0.01 | +$0.10 |
| Q4 2025 | $0.03 | +$0.15 |
| Q3 2025 | $0.01 | +$0.13 |
| Q2 2025 | -$0.04 | -$0.03 |
| Q1 2025 | -$0.09 | -$0.09 |
| Q4 2024 | -$0.12 | -1300% |
| Q3 2024 | -$0.12 | -700% |
XTNT is still losing money, but far less than before: $0.08 per share over the past year, against $5.15 at its worst in late 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over XTNT on profitability, with a higher operating margin.
XTNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23M | -35% |
| Q1 2026 | $20.9M | -37% |
| Q4 2025 | $32.4M | +2.7% |
| Q3 2025 | $33.3M | +19% |
| Q2 2025 | $35.4M | +18% |
| Q1 2025 | $32.9M | +18% |
| Q4 2024 | $31.5M | +12% |
| Q3 2024 | $27.9M | +12% |
XTNT's revenue has slid since its 2025 peak: $23M last quarter, down 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -40% | -53 points |
| Q1 2026 | -14% | -17 points |
| Q4 2025 | -2.9% | +3 points |
| Q3 2025 | 7.6% | +21 points |
| Q2 2025 | 13% | +23 points |
| Q1 2025 | 3.2% | +16 points |
| Q4 2024 | -6% | +7.6 points |
| Q3 2024 | -14% | 0 points |
XTNT's operating margin was −40% last quarter, down 53 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over XTNT on cash generation, producing positive trailing cash flow while its opponent burns cash.
XTNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.6M | -930% |
| Q1 2026 | -$2.3M | -2753% |
| Q4 2025 | $5M | +$5M |
| Q3 2025 | $4.2M | +$8M |
| Q2 2025 | $910K | +$6.6M |
| Q1 2025 | $87K | +$6.6M |
| Q4 2024 | -$7K | +$1.3M |
| Q3 2024 | -$3.8M | +$235K |
XTNT has burned cash in most quarters: −$696,000 over the past year, against −$3M the year before.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
XTNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 3.4x | Elevated |
| Q2 2021 | -4.0x | Net Cash |
| Q1 2021 | -0.9x | Net Cash |
| Q4 2020 | 10.9x | High |
| Q3 2020 | 66.6x | High |
XTNT has more cash than debt.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
XTNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 5.3 | Oversold |
XTNT's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
XTNT PE vs Healthcare Sector
| Metric | XTNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XTNT has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over XTNT on trend strength, trading above more of its moving averages.
XTNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.31 | 9.7% below |
| 20 week MA | $0.35 | 20% below |
| 50 week MA | $0.49 | 43% below |
| 100 week MA | $0.54 | 48% below |
| 200 week MA | $0.69 | 59% below |
XTNT is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over XTNT on returns for 2026, with the stronger performance.
XTNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.67 | $1.20 | -28% |
| 2021 | $1.20 | $0.66 | -45% |
| 2022 | $0.66 | $0.66 | 0% |
| 2023 | $0.66 | $1.13 | +71% |
| 2024 | $1.13 | $0.46 | -59% |
| 2025 | $0.46 | $0.78 | +70% |
| 2026 YTD | $0.78 | $0.28 | -64% |
XTNT has finished lower in four of the last six years. It's down 64% so far in 2026.